Patents Assigned to SIOLTA THERAPEUTICS, INC.
  • Therapeutic pharmaceutical compositions
    Patent number: 11806373
    Abstract: Provided herein are pharmaceutical compositions comprising a bacterial consortium and one or more pharmaceutically acceptable excipients. Such pharmaceutical compositions can be orally administered to a subject for prevention and/or treatment of dysbiosis, dysbiosis associated conditions, inflammation, and autoimmune diseases.
    Type: Grant
    Filed: May 25, 2022
    Date of Patent: November 7, 2023
    Assignee: SIOLTA THERAPEUTICS, INC.
    Inventors: Nikole Kimes, Ricardo Valladares, Neeraja Vajrala
  • Therapeutic pharmaceutical compositions
    Patent number: 11406675
    Abstract: Provided herein are pharmaceutical compositions comprising a bacterial consortium and one or more pharmaceutically acceptable excipients. Such pharmaceutical compositions can be orally administered to a subject for prevention and/or treatment of dysbiosis, dysbiosis associated conditions, inflammation, and autoimmune diseases.
    Type: Grant
    Filed: September 14, 2021
    Date of Patent: August 9, 2022
    Assignee: Siolta Therapeutics, Inc.
    Inventors: Nikole Kimes, Ricardo Valladares, Neeraja Vajrala
  • Microbial consortia
    Patent number: 11369644
    Abstract: Provided herein are microbial strains isolated de novo. In some instances, the bacterial strains include genera, species, and/or strains of Lactobacillus johnsonii, Lactobacillus crispatus, Faecalibacterium prausnitzii, Akkermansia muciniphila, Bifidobacterium longum, and/or Bifidobacterium longum infantis strains. These bacterial strains can be used in the treatment of dysbiosis, inflammation, and other disorders.
    Type: Grant
    Filed: October 9, 2020
    Date of Patent: June 28, 2022
    Assignees: SIOLTA THERAPEUTICS, INC., THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Nikole Kimes, Ricardo Valladares, Benjamin Fiebiger, Susan V. Lynch